BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? NASDAQ · Markets 45m ago
Trump Accounts top 70 million as new stock-donation rules open door to 'mega donors,' official says CNBC · Economy 48m ago